These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6894282)

  • 1. Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.
    Tawara K; Kawashima K; Ishikawa H; Yamamoto K; Saito K; Ebihara A; Yoshida S
    Eur J Clin Pharmacol; 1981 Feb; 19(3):197-203. PubMed ID: 6894282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of thyroid dysfunction on propranolol kinetics.
    Riddell JG; Neill JD; Kelly JG; McDevitt DG
    Clin Pharmacol Ther; 1980 Nov; 28(5):565-74. PubMed ID: 7438675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No enhanced elimination of propranolol in patients with hyperthyroidism.
    Ishizaki T; Masuno M; Tawara K
    Res Commun Chem Pathol Pharmacol; 1980 Sep; 29(3):473-85. PubMed ID: 7423023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of propranolol isomers and their relationships with beta adrenoceptor blocking activity in rabbits administered with dl-propranolol.
    Kawashima K; Ishikawa H
    J Pharmacol Exp Ther; 1980 Jun; 213(3):628-31. PubMed ID: 6110769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of changes in drug disposition and catecholamine sensitivity in the hyperthyroid dog.
    Ishizaki T; Tawara K
    Br J Pharmacol; 1980; 71(1):143-55. PubMed ID: 7470733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of propranolol and sotalol in hyperthyroidism.
    Aro A; Anttila M; Korhonen T; Sundquist H
    Eur J Clin Pharmacol; 1982; 21(5):373-7. PubMed ID: 7075642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective disposition and glucuronidation of propranolol in humans.
    Silber B; Holford NH; Riegelman S
    J Pharm Sci; 1982 Jun; 71(6):699-704. PubMed ID: 7097538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of age on the protein binding and disposition of propranolol stereoisomers.
    Lalonde RL; Tenero DM; Burlew BS; Herring VL; Bottorff MB
    Clin Pharmacol Ther; 1990 Apr; 47(4):447-55. PubMed ID: 2328552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective clearance and distribution of intravenous propranolol.
    Olanoff LS; Walle T; Walle UK; Cowart TD; Gaffney TE
    Clin Pharmacol Ther; 1984 Jun; 35(6):755-61. PubMed ID: 6734027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog.
    Bai SA; Abramson FP
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):333-49. PubMed ID: 6502474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.
    Wells PG; Feely J; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1983 May; 33(5):603-8. PubMed ID: 6839632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.
    Williams FM; Leeser JE; Rawlins MD
    Br J Clin Pharmacol; 1986 Sep; 22(3):301-8. PubMed ID: 3768242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
    Bowman SL; Hudson SA; Simpson G; Munro JF; Clements JA
    Br J Clin Pharmacol; 1986 May; 21(5):529-32. PubMed ID: 3718810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereospecific and circadian-phase-dependent kinetic behavior of d,l-, l-, and d-propranolol in plasma, heart, and brain of light--dark-synchronized rats.
    Lemmer B; Bathe K
    J Cardiovasc Pharmacol; 1982; 4(4):635-44. PubMed ID: 6181339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.
    Wellstein A; Palm D; Pitschner HF; Belz GG
    Eur J Clin Pharmacol; 1985; 29(2):131-47. PubMed ID: 3000793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of propranolol: a review.
    Shand DG
    Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.
    Hallengren B; Nilsson OR; Karlberg BE; Melander A; Tegler L; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1982; 21(5):379-84. PubMed ID: 7075643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.